Skip to main content
letter
. 2019 May;104(5):e208–e210. doi: 10.3324/haematol.2018.198820

Figure 1.

Figure 1.

Progression-free survival (PFS) and overall survival (OS) for patients included in the compassionate use program (CUP). Survival analyses from start of treatment until event using the Kaplan-Meier method. (A) PFS and (B) OS of all patients. (C) PFS and (D) OS of CUP patients matching versus not matching the RESONATE trial inclusion criteria. (E) PFS and (F) OS of CUP patients with dose reduction versus no dose reduction. (G) PFS and (H) OS of CUP patients with treatment break versus no treatment break.